Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Identification of New Virulence Factors and Vaccine Candidates for Yersinia pestis.

Andersson JA, Sha J, Erova TE, Fitts EC, Ponnusamy D, Kozlova EV, Kirtley ML, Chopra AK.

Front Cell Infect Microbiol. 2017 Oct 17;7:448. doi: 10.3389/fcimb.2017.00448. eCollection 2017.

2.

A Bivalent Anthrax-Plague Vaccine That Can Protect against Two Tier-1 Bioterror Pathogens, Bacillus anthracis and Yersinia pestis.

Tao P, Mahalingam M, Zhu J, Moayeri M, Kirtley ML, Fitts EC, Andersson JA, Lawrence WS, Leppla SH, Chopra AK, Rao VB.

Front Immunol. 2017 Jun 26;8:687. doi: 10.3389/fimmu.2017.00687. eCollection 2017.

3.

Immunogenicity and safety of subunit plague vaccine: A randomized phase 2a clinical trial.

Chu K, Hu J, Meng F, Li J, Luo L, Xu J, Yuan Z, Li Z, Chen W, Jiao L, Chang Y, Wang B, Hu Y.

Hum Vaccin Immunother. 2016 Sep;12(9):2334-40. doi: 10.1080/21645515.2016.1175261. Epub 2016 May 9.

4.

Recombinant Bivalent Fusion Protein rVE Induces CD4+ and CD8+ T-Cell Mediated Memory Immune Response for Protection Against Yersinia enterocolitica Infection.

Singh AK, Kingston JJ, Gupta SK, Batra HV.

Front Microbiol. 2015 Dec 16;6:1407. doi: 10.3389/fmicb.2015.01407. eCollection 2015.

5.

Plague: Infections of Companion Animals and Opportunities for Intervention.

Oyston PC, Williamson D.

Animals (Basel). 2011 Jun 21;1(2):242-55. doi: 10.3390/ani1020242. Review.

6.
7.

Plague vaccines: current developments and future perspectives.

Feodorova VA, Motin VL.

Emerg Microbes Infect. 2012 Nov;1(11):e36. doi: 10.1038/emi.2012.34. Epub 2012 Nov 7. Review.

8.

Further characterization of a highly attenuated Yersinia pestis CO92 mutant deleted for the genes encoding Braun lipoprotein and plasminogen activator protease in murine alveolar and primary human macrophages.

van Lier CJ, Tiner BL, Chauhan S, Motin VL, Fitts EC, Huante MB, Endsley JJ, Ponnusamy D, Sha J, Chopra AK.

Microb Pathog. 2015 Mar;80:27-38. doi: 10.1016/j.micpath.2015.02.005. Epub 2015 Feb 16.

9.

The impact of "omic" and imaging technologies on assessing the host immune response to biodefence agents.

Tree JA, Flick-Smith H, Elmore MJ, Rowland CA.

J Immunol Res. 2014;2014:237043. doi: 10.1155/2014/237043. Epub 2014 Sep 16. Review.

10.

LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.

Sun W, Sanapala S, Henderson JC, Sam S, Olinzock J, Trent MS, Curtiss R 3rd.

Infect Immun. 2014 Oct;82(10):4390-404. doi: 10.1128/IAI.02173-14. Epub 2014 Aug 11.

11.

Efficacy of primate humoral passive transfer in a murine model of pneumonic plague is mouse strain-dependent.

Graham VA, Hatch GJ, Bewley KR, Steeds K, Lansley A, Bate SR, Funnell SG.

J Immunol Res. 2014;2014:807564. doi: 10.1155/2014/807564. Epub 2014 Jul 6.

12.

Deletion of Braun lipoprotein and plasminogen-activating protease-encoding genes attenuates Yersinia pestis in mouse models of bubonic and pneumonic plague.

van Lier CJ, Sha J, Kirtley ML, Cao A, Tiner BL, Erova TE, Cong Y, Kozlova EV, Popov VL, Baze WB, Chopra AK.

Infect Immun. 2014 Jun;82(6):2485-503. doi: 10.1128/IAI.01595-13. Epub 2014 Mar 31.

13.

A systems approach to designing next generation vaccines: combining α-galactose modified antigens with nanoparticle platforms.

Phanse Y, Carrillo-Conde BR, Ramer-Tait AE, Broderick S, Kong CS, Rajan K, Flick R, Mandell RB, Narasimhan B, Wannemuehler MJ.

Sci Rep. 2014 Jan 20;4:3775. doi: 10.1038/srep03775.

14.

Plague gives surprises in the first decade of the 21st century in the United States and worldwide.

Butler T.

Am J Trop Med Hyg. 2013 Oct;89(4):788-93. doi: 10.4269/ajtmh.13-0191. Epub 2013 Sep 16. Review.

15.

Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines.

Tao P, Mahalingam M, Kirtley ML, van Lier CJ, Sha J, Yeager LA, Chopra AK, Rao VB.

PLoS Pathog. 2013;9(7):e1003495. doi: 10.1371/journal.ppat.1003495. Epub 2013 Jul 11.

16.

Protecting against plague: towards a next-generation vaccine.

Williamson ED, Oyston PC.

Clin Exp Immunol. 2013 Apr;172(1):1-8. doi: 10.1111/cei.12044. Review.

17.

Characterization of systemic and pneumonic murine models of plague infection using a conditionally virulent strain.

Mellado-Sanchez G, Ramirez K, Drachenberg CB, Diaz-McNair J, Rodriguez AL, Galen JE, Nataro JP, Pasetti MF.

Comp Immunol Microbiol Infect Dis. 2013 Mar;36(2):113-28. doi: 10.1016/j.cimid.2012.10.005. Epub 2012 Nov 26.

18.

Conjugation of Y. pestis F1-antigen to gold nanoparticles improves immunogenicity.

Gregory AE, Williamson ED, Prior JL, Butcher WA, Thompson IJ, Shaw AM, Titball RW.

Vaccine. 2012 Nov 6;30(48):6777-82. doi: 10.1016/j.vaccine.2012.09.021. Epub 2012 Sep 18.

19.

Polymorphisms in the lcrV gene of Yersinia enterocolitica and their effect on plague protective immunity.

Miller NC, Quenee LE, Elli D, Ciletti NA, Schneewind O.

Infect Immun. 2012 Apr;80(4):1572-82. doi: 10.1128/IAI.05637-11. Epub 2012 Jan 17.

20.

Humoral and cellular immune responses to Yersinia pestis infection in long-term recovered plague patients.

Li B, Du C, Zhou L, Bi Y, Wang X, Wen L, Guo Z, Song Z, Yang R.

Clin Vaccine Immunol. 2012 Feb;19(2):228-34. doi: 10.1128/CVI.05559-11. Epub 2011 Dec 21.

Supplemental Content

Support Center